GlaxoSmithKline PLC has agreed to pay the U.S. Internal Revenue Service about $3.4 billion to settle a dispute over the way it valued the profits of its ulcer medication Zantac, allergy drug Flonase and a half-dozen other key products. The U.S. tax agency, in a statement, said today its settlement with the U.S.
Most Popular
13 Job Interview Mistakes To Avoid
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
subsidiaries of GlaxoSmithKline involves “the largest single payment made to the IRS to resolve a tax dispute.” The dispute, over a practice called “transfer pricing,” centered on the level of GlaxoSmithKline’s reported U.S. profits on certain products and the amount of “intercompany” transfers between its British parent corporation and its U.S. subsidiaries. Other multinational drug companies are involved in similar disputes with the IRS. Mark W. Everson, the commissioner of Internal Revenue, said the settlement “sends a strong message of our resolve to continue to deal with” the complex corporate issue of transfer pricing. elavil. “I am pleased …
Read the full article with a Free Trial at MyWire.